1. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Issue 8 (30th January 2020) Authors: Biederstädt, Alexander; Hassan, Zonera; Schneeweis, Christian; Schick, Markus; Schneider, Lara; Muckenhuber, Alexander; Hong, Yingfen; Siegers, Gerrit; Nilsson, Lisa; Wirth, Matthias; Dantes, Zahra; Steiger, Katja; Schunck, Kathrin; Langston, Steve; Lenhof, H-P; Coluccio, Andrea; Orben, Felix; Sl... Journal: Gut Issue: Volume 69:Issue 8(2020) Page Start: 1472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems. Issue 4 (4th February 2022) Authors: Peschke, Katja; Jakubowsky, Hannah; Schäfer, Arlett; Maurer, Carlo; Lange, Sebastian; Orben, Felix; Bernad, Raquel; Harder, Felix N; Eiber, Matthias; Öllinger, Rupert; Steiger, Katja; Schlitter, Melissa; Weichert, Wilko; Mayr, Ulrich; Phillip, Veit; Schlag, Christoph; Schmid, Roland M; Braren, Ri... Journal: EMBO molecular medicine Issue: Volume 14:Issue 4(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Issue 4 (7th March 2022) Authors: Schneeweis, Christian; Hassan, Zonera; Ascherl, Katja; Wirth, Matthias; Koutsouli, Stella; Orben, Felix; Krauß, Lukas; Schneider, Carolin; Öllinger, Rupert; Krämer, Oliver H.; Rad, Roland; Reichert, Maximilian; Robles, Maria S.; Saur, Dieter; Schneider, Günter Journal: Cancer communications Issue: Volume 42:Issue 4(2022) Page Start: 360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗